Saturday, December 3, 2022

561.316.3330

Biotechnology News Magazine

Trinity Life Sciences Acquires Vancery’s Customer Research Technology

Latest Posts

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Acer Therapeutics Announces $1.5M Private Placement

The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer’s disease (AD).

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode Therapeutics believes that TTX-MC138 could be used as a treatment for many of these cancers.

Trinity Life Sciences, a leader in global life sciences commercialization solutions, announced it signed an asset purchase agreement for the acquisition of Vancery’s customer research technology.

The investment expands Trinity’s insights and analytics product offerings, allowing the company to better connect with healthcare professionals to inform commercial strategy for its clients. The new technology will improve primary market research in the life sciences by integrating advanced research methods with an enhanced respondent experience to drive higher quality insights.

“We are thrilled to bring the sophisticated customer research technology that Vancery built to the healthcare space,” said Aparna Deshpande, PhD, Senior Partner, Insights. “Now, more than ever, payer, patient and healthcare provider research are critical in making sure treatments are available ASAP to those in need.”

Besides the technology acquisition, a team of experts from Vancery will join Trinity to continue to support and transform the software for use in healthcare.

“I am so proud of what the Vancery team has built and delighted that Trinity will bring our technology and vision to the next level,” said Gunnar Gregory, CEO, Vancery. “With Trinity, our unique technologies will help incorporate qualitative and quantitative research into their life science clients’ daily decision-making.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine